Elevance Health (ELV) Lifted Full Year Guidance, Is The 11% Undervaluation Still There?

Simply Wall St.07-24

Elevance Health (ELV) shares are in focus after the company paired its second quarter earnings release with higher full year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653776648?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160","is_english":true,"pubTime":"2026-07-24 03:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653776648","market":"hk","top_or_hot":-1,"title":"Elevance Health (ELV) Lifted Full Year Guidance, Is The 11% Undervaluation Still There?","media":"Simply Wall St.","content":"<div>\n<p>Elevance Health (ELV) shares are in focus after the company paired its second quarter earnings release with higher full year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-lifted-full-year-guidance-is-the-11-unde\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elevance Health (ELV) Lifted Full Year Guidance, Is The 11% Undervaluation Still There?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElevance Health (ELV) Lifted Full Year Guidance, Is The 11% Undervaluation Still There?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-24 03:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-lifted-full-year-guidance-is-the-11-unde><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Elevance Health (ELV) shares are in focus after the company paired its second quarter earnings release with higher full year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-lifted-full-year-guidance-is-the-11-unde\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314106906.USD","symbol_name":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-lifted-full-year-guidance-is-the-11-unde","article_id":"2653776648","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-lifted-full-year-guidance-is-the-11-unde","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653776648","pubTimestamp":1784834959,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Elevance Health (ELV) shares are in focus after the company paired its second quarter earnings release with higher full year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net income.\nSee our latest analysis for Elevance Health.\nThe share price reaction to Elevance Health's updated guidance has come after a stronger run earlier in the year, with the 90 day share price return up 12.36% and the 1 year total shareholder return at 33.94%. The 3 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","ELV.AU":"ELEVRA LITHIUM LTD","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0061474960.USD":"天利环球焦点基金AU Acc","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","VGFPF":"Vanguard Funds PLC","IHF":"iShares Dow Jones U.S. Health Ca","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0557290698.USD":"施罗德环球可持续增长基金","ELV":"Elevance Health","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","JOYT":"JPMorgan Equity and Options Total Return ETF","GXDW":"Global X Dorsey Wright Thematic ETF","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1815333072.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"AUP\" (USD) INC","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","VOTE":"TCW Transform 500 ETF","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","RGLO":"Global Equity Active ETF","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","PMDE":"PGIM S&P 500 Max Buffer ETF - December","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4588":"碎股","BK4154":"管理型保健护理","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H"},"translate_title":"Elevance Health (ELV) 上调全年指引，11% 的低估还存在吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FEBU":0.64,"DECU":0.64,"VOTE":0.64,"IHF":0.6,"PMDE":0.64,"GXDW":0.64,"VGFPF":0.64,"ELV":1.5,"ELV.AU":1.5,"RGLO":0.64,"JOYT":0.64},"content_text":"Elevance Health (ELV) shares are in focus after the company paired its second quarter earnings release with higher full year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net income. See our latest analysis for Elevance Health. The share price reaction to Elevance Health's updated guidance has come after a stronger run earlier in the year, with the 90 day share price return up 12.36% and the 1 year total shareholder return at 33.94%. The 3 year total shareholder return is down 12.97% and the 5 year total shareholder return is 10.04%, suggesting recent momentum has picked up compared with longer term performance. If this earnings update has you reassessing healthcare exposure, it can be helpful to see what else is moving in related areas, including companies using AI in medical and health services via the 41 healthcare AI stocks. Bulls point to Elevance Health's raised 2026 EPS floor and ongoing buybacks, while bears focus on the softer quarterly earnings. Which side does the current valuation argument appear to favor at this point? AdvertisementMost Popular Narrative: 10.9% Undervalued Against Elevance Health's last close of $389.09, the most followed narrative points to a fair value of $436.52, framing the earnings guidance upgrade within a modest valuation gap.  Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams, which should drive both topline and earnings diversity as industry healthcare spending and complexity continue to rise.  Read the complete narrative. Want to see what is baked into that higher fair value for Elevance Health? Revenue mix shifts, margin rebuild assumptions and a future earnings multiple all sit at the core of this narrative. Result: Fair Value of $436.52 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that fair value story for Elevance Health still hinges on Medicaid margins improving and medical cost trends not staying elevated in ACA and government programs. Find out about the key risks to this Elevance Health narrative. Next Steps With Elevance Health's story pulling in different directions, it can help to look beyond headlines and put the numbers into your own context. To see what optimism around the stock's potential rewards looks like, start by reviewing the 4 key rewards Looking for more investment ideas beyond Elevance Health? If Elevance Health has you thinking more broadly about your portfolio, do not sit on the sidelines while other opportunities line up on your radar.  Target long term compounding potential by reviewing companies flagged in the 47 high quality undervalued stocks. Strengthen your income stream by checking out stocks highlighted in the 7 dividend fortresses. Dial down portfolio shocks by focusing on companies surfaced through the 82 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elevance Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653776648","isCrawlerRequest":true}